These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 32340843)
1. Patient-derived tumor organoid predicts drugs response in glioblastoma: A step forward in personalized cancer therapy? Loong HH; Wong AM; Chan DT; Cheung MS; Chow C; Ding X; Chan AK; Johnston PA; Lau JY; Poon WS; Wong N J Clin Neurosci; 2020 Aug; 78():400-402. PubMed ID: 32340843 [TBL] [Abstract][Full Text] [Related]
2. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264 [TBL] [Abstract][Full Text] [Related]
3. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Daher A; de Groot J Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369 [TBL] [Abstract][Full Text] [Related]
4. Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review). Bryukhovetskiy I; Bryukhovetskiy A; Khotimchenko Y; Mischenko P Oncol Rep; 2016 Feb; 35(2):639-48. PubMed ID: 26548844 [TBL] [Abstract][Full Text] [Related]
5. Organoid technology in cancer precision medicine. Xia X; Li F; He J; Aji R; Gao D Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736 [TBL] [Abstract][Full Text] [Related]
6. Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics. Krieger TG; Tirier SM; Park J; Jechow K; Eisemann T; Peterziel H; Angel P; Eils R; Conrad C Neuro Oncol; 2020 Aug; 22(8):1138-1149. PubMed ID: 32297954 [TBL] [Abstract][Full Text] [Related]
7. Development of glioblastoma organoids and their applications in personalized therapy. Xu C; Yuan X; Hou P; Li Z; Wang C; Fang C; Tan Y Cancer Biol Med; 2023 Jun; 20(5):353-68. PubMed ID: 37283493 [TBL] [Abstract][Full Text] [Related]
8. Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion. Darrigues E; Zhao EH; De Loose A; Lee MP; Borrelli MJ; Eoff RL; Galileo DS; Penthala NR; Crooks PA; Rodriguez A Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639060 [TBL] [Abstract][Full Text] [Related]
9. The challenges associated with molecular targeted therapies for glioblastoma. Jue TR; McDonald KL J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075 [TBL] [Abstract][Full Text] [Related]
10. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897 [TBL] [Abstract][Full Text] [Related]
11. [Targeted therapy in glioblastoma: update and perspectives]. Idbaih A; Duran-Peña A; Alentorn A Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421 [TBL] [Abstract][Full Text] [Related]
12. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review). Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540 [TBL] [Abstract][Full Text] [Related]
13. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy. Spencer DA; Auffinger BM; Murphy JP; Muroski ME; Qiao J; Gorind Y; Lesniak MS Curr Cancer Drug Targets; 2017; 17(3):236-254. PubMed ID: 27993114 [TBL] [Abstract][Full Text] [Related]
14. Individualized targeted therapy for glioblastoma: fact or fiction? Weller M; Stupp R; Hegi M; Wick W Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256 [TBL] [Abstract][Full Text] [Related]
15. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer. Urbaniak A; Reed MR; Heflin B; Gaydos J; Piña-Oviedo S; Jędrzejczyk M; Klejborowska G; Stępczyńska N; Chambers TC; Tackett AJ; Rodriguez A; Huczyński A; Eoff RL; MacNicol AM Biomed Pharmacother; 2022 Sep; 153():113440. PubMed ID: 36076555 [TBL] [Abstract][Full Text] [Related]
16. Facilitating tailored therapeutic strategies for glioblastoma through an orthotopic patient-derived xenograft platform. Lee HW; Lee K; Kim DG; Yang H; Nam DH Histol Histopathol; 2016 Mar; 31(3):269-83. PubMed ID: 26578300 [TBL] [Abstract][Full Text] [Related]
17. Identifying glioblastoma gene networks based on hypergeometric test analysis. Stathias V; Pastori C; Griffin TZ; Komotar R; Clarke J; Zhang M; Ayad NG PLoS One; 2014; 9(12):e115842. PubMed ID: 25551752 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response. Verduin M; Compter I; Steijvers D; Postma AA; Eekers DBP; Anten MM; Ackermans L; Ter Laan M; Leijenaar RTH; van de Weijer T; Tjan-Heijnen VCG; Hoeben A; Vooijs M Dis Markers; 2018; 2018():2908609. PubMed ID: 29581794 [TBL] [Abstract][Full Text] [Related]
19. Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. Šamec N; Zottel A; Videtič Paska A; Jovčevska I Molecules; 2020 Jan; 25(3):. PubMed ID: 31979318 [TBL] [Abstract][Full Text] [Related]
20. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential. Anthony C; Mladkova-Suchy N; Adamson DC Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114 [No Abstract] [Full Text] [Related] [Next] [New Search]